Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Time to Bring "New Growth Story" To Investors

307 Views22 May 2024 08:55
Mindray is currently facing the dilemma of sluggish growth. YoY revenue growth would further decrease to 15% in the future. Without "new growth stories", there is no reason to maintain high valuation.
What is covered in the Full Insight:
  • Low end 2023 growth
  • Possible failure to reach 20% revenue growth in 2024
  • Reasonable valuation
  • Challenges in internationalization
  • Eagerness to find new growth points
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x